☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Schizophrenia
Neurocrine Signs a License Agreement with Sosei Heptares to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other...
November 23, 2021
Janssen's Invega Hafyera (paliperidone palmitate) Receives the US FDA's Approval for the Treatment of Schizophrenia
September 2, 2021
Boehringer Ingelheim's BI 425809 Receives the US FDA's Breakthrough Therapy Designation for Cognitive Impairment Associated with S...
May 25, 2021
BioXcel Reports the US FDA's Acceptance of BXCL501's NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bi...
May 19, 2021
Janssen Reports sNDA Submission of Paliperidone Palmitate 6-Month (PP6M) to the US FDA for Schizophrenia
November 3, 2020
Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Patients with Schizophrenia
September 15, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.